National Center for Health Statistics, Meeting of the ICD-10 Coordination and Maintenance Committee, 7710-7711 [2024-02178]
Download as PDF
7710
Federal Register / Vol. 89, No. 24 / Monday, February 5, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Center for Health Statistics,
Meeting of the ICD–10 Coordination
and Maintenance Committee
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), National
Center for Health Statistics (NCHS),
Classifications and Public Health Data
Standards Staff, announces the
following meeting of the ICD–10
Coordination and Maintenance (C&M)
Committee. This meeting is open to the
public, limited only by the number of
audio lines available. Online
registration is required.
DATES: The meeting will be held on
March 19, 2024, from 9 a.m. to 5 p.m.,
EDT, and March 20, 2024, from 9 a.m.
to 5 p.m., EDT.
ADDRESSES: This is a virtual meeting.
Register in advance at https://
cms.zoomgov.com/webinar/register/
WN_zqbhSXNtSEmAVWJhs4-4kA. The
Webinar ID is 161 010 6901; the
Passcode is 681647. After registering,
you will receive a confirmation email
containing information about joining the
meeting. Further information will be
provided on each of the respective web
pages when it becomes available. For
CDC, NCHS: https://www.cdc.gov/nchs/
icd/icd10cm_maintenance.htm. For the
Centers for Medicare & Medicaid
Services, Department of Health and
Human Services: https://www.cms.gov/
medicare/coding-billing/icd-10-codes/
icd-10-coordination-maintenancecommittee-materials.
FOR FURTHER INFORMATION CONTACT:
Traci Ramirez, Medical Classification
Specialist, National Center for Health
Statistics, Centers for Disease Control
and Prevention, 3311 Toledo Road,
Hyattsville, Maryland 20782–2064.
Telephone: (301) 458–4454; Email:
TRamirez@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The ICD–10 Coordination
and Maintenance (C&M) Committee is a
public forum for the presentation of
proposed modifications to the
International Classification of Diseases,
Tenth Revision, Clinical Modification
(CM) and ICD–10 Procedure Coding
System (PCS).
Matters to be Considered: The
tentative agenda will include
discussions on the ICD–10–CM and
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:56 Feb 02, 2024
Jkt 262001
ICD–10–PCS topics listed below.
Agenda items are subject to change as
priorities dictate. Please refer to the
posted agenda for updates one month
prior to the meeting.
ICD–10–PCS Topics:
1. Restriction Using Thoracoabdominal
Branch Endoprosthesis *
2. Tibiotalocalcaneal Fusion with
Fixation Implant *
3. Fiber Optic 3D Real-time Device
Guidance **
4. Visualization and Analysis of Brain
Networks in Magnetic Resonance
Imaging *
5. Lymphatic Bypass
6. Performance of Circulatory Filtration
7. Quantitative Antimicrobial
Susceptibility Testing of Blood
Cultures
8. Transcatheter Tricuspid Valve
Replacement *
9. Cellular Assessment via Microfluidic
Deformability Cytometry **
10. Fixation of Lumbar Facet Joint
11. Extracorporeal Blood Pathogen
Removal **
12. Application of prademagene
zamikeracel **
13. Adoptive Immune Therapy
14. Administration of dasiglucagon
15. Drug-eluting Resorbable Scaffold
System
16. Continuous Monitoring and
Assessment of Vascular Blood
Flow *
17. Paclitaxel-coated Balloon Catheter
for Percutaneous Coronary
Intervention
18. Division of Bioprosthetic Aortic
Valve Leaflets **
19. Computer-aided Triage and
Notification for Measurement of
Intracranial Cerebrospinal Fluid
Flow *
20. Implantation of Bioengineered
Vessel **
21. Rapid Antimicrobial Susceptibility
Testing of Blood Cultures *
22. Stereoelectroencephalographic
Radiofrequency Ablation of Brain
and Nervous Tissue
23. Insertion of Antibiotic Instilling
Joint Spacer **
24. Posterior Fixation of the
Thoracolumbar Spine *
25. Section X Updates
26. Addenda and Key Updates
27. Administration of bentracimab **
28. Administration of cefepimetaniborbactam *
29. Administration of ceftobiprole
medocaril *
30. Administration of obecabtagene
autoleucel **
31. Administration of odronextamab *
32. Administration of Orca-T **
33. Administration of RP–L201
(marnetegragene autotemcel) *
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
34. Administration of zanidatamab **
35. Donislecel-jujn Allogeneic
Pancreatic Islet Cellular Suspension
for Hepatic Portal Vein Infusion *
* Requestor has submitted a new
technology add-on payment (NTAP)
application for FY 2025 consideration.
** Request is for an October 1, 2024,
implementation date, and the requestor
intends to submit an NTAP application
for FY 2026 consideration.
Presentations for procedure code
requests are conducted by both the
requestor and the Centers for Medicare
& Medicaid Services (CMS) during the
C&M Committee meeting. Discussion
from the requestor generally focuses on
the clinical issues for the procedure or
technology, followed by the proposed
coding options from a CMS analyst.
Topics presented may also include
requests for new procedure codes that
relate to a new technology add-on
payment (NTAP) policy request.
CMS has modified the approach for
presenting the new NTAP-related ICD–
10–PCS procedure code requests that
involve the administration of a
therapeutic agent. For the March 19–20,
2024, ICD–10 C&M Committee meeting,
consistent with the requirements of
section 1886(d)(5)(K)(iii) of the Social
Security Act, applicants submitted
requests to create a unique procedure
code to describe the administration of a
therapeutic agent, such as the option to
create a new code in Section X within
the ICD–10–PCS procedure code
classification. CMS will initially display
only those meeting materials associated
with the NTAP-related ICD–10–PCS
procedure code requests that involve the
administration of a therapeutic agent on
the CMS website in early March 2024 at:
https://www.cms.gov/medicare/codingbilling/icd-10-codes/icd-10coordination-maintenance-committeematerials.
The nine NTAP-related ICD–10–PCS
procedure code requests that involve the
administration of a therapeutic agent
are:
1. Administration of bentracimab **
2. Administration of cefepimetaniborbactam *
3. Administration of ceftobiprole
medocaril *
4. Administration of obecabtagene
autoleucel **
5. Administration of odronextamab *
6. Administration of Orca-T **
7. Administration of RP–L201
(marnetegragene autotemcel) *
8. Administration of zanidatamab **
9. Donislecel-jujn Allogeneic Pancreatic
Islet Cellular Suspension for
Hepatic Portal Vein Infusion *
* Requestor has submitted an NTAP
application for FY 2025 consideration.
E:\FR\FM\05FEN1.SGM
05FEN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 24 / Monday, February 5, 2024 / Notices
** Request is for an October 1, 2024,
implementation date, and the requestor
intends to submit an NTAP application
for FY 2026 consideration.
These topics will not be presented
during the March 19–20, 2024, meeting.
CMS will solicit public comments
regarding any clinical questions or
coding options included for these
procedure code topics in advance of the
meeting continuing through the end of
the respective public comment periods.
Members of the public should send any
questions or comments to the CMS
mailbox at: ICDProcedureCodeRequest@
cms.hhs.gov.
CMS intends to post a question-andanswer document in advance of the
meeting to address any clinical or
coding questions that members of the
public may have submitted. Following
the conclusion of the meeting, CMS will
post an updated question-and-answer
document to address any additional
clinical or coding questions that
members of the public may have
submitted during the meeting that CMS
was not able to address or that were
submitted after the meeting.
The NTAP-related ICD–10–PCS
procedure code requests that do not
involve the administration of a
therapeutic agent and all non-NTAPrelated procedure code requests will
continue to be presented during the
virtual meeting on March 19, 2024,
consistent with the standard meeting
process.
CMS will make all meeting materials
and related documents available at:
https://www.cms.gov/medicare/codingbilling/icd-10-codes/icd-10coordination-maintenance-committeematerials. Any inquiries related to the
procedure code topics scheduled for the
March 19, 2024, ICD–10 C&M
Committee meeting day that are under
consideration for October 1, 2024,
implementation should be sent to the
CMS mailbox at:
ICDProcedureCodeRequest@
cms.hhs.gov.
ICD–10–CM Topics:
1. Abnormal Anti-cyclic Citrullinated
Peptide Antibody and/or
Rheumatoid Factor Without Current
or Prior Clinical Diagnosis of
Rheumatoid Arthritis
2. APOL1-mediated Kidney Disease
3. Baked Egg Tolerance
4. Baked Milk Tolerance
5. Coding of Firearms Injuries Default
6. DLG4-related Synaptopathy
7. Flank Anatomical Specificity
8. Glutamate Receptor, Ionotropic,
Gene-related Neurodevelopmental
Disorders
9. Gulf War Illness
VerDate Sep<11>2014
17:56 Feb 02, 2024
Jkt 262001
10. Hyperoxaluria
11. Post-exertional Malaise
12. SCN2A-related Disorders
13. SLC6A1-related Disorders
14. STXBP1-related Disorders
15. Usher Syndrome
16. Addenda
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–02178 Filed 2–2–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–24–1402]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Surveillance of
HIV-related service barriers among
Individuals with Early or Late HIV
Diagnoses (SHIELD)’’ to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on October
06, 2023, to obtain comments from the
public and affected agencies. CDC
received two comments to the previous
notice. This notice serves to allow an
additional 30 days for public and
affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
7711
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Surveillance of HIV-related service
barriers among Individuals with Early or
Late HIV Diagnoses (SHIELD) (OMB
Control No. 0920–1402, Exp. 05/31/
2026)—Revision—National Center for
HIV, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
National HIV Surveillance System
(NHSS) data indicate that 36,940
adolescents and adults received an HIV
diagnosis in the United States and
dependent areas in 2019. During 2015–
2019, the overall rate of annual
diagnoses decreased only slightly, from
12.4 to 11.1 per 100,000 persons.
Although not every jurisdiction reports
complete laboratory data needed to
identify the stage of infection, data from
the majority of jurisdictions show that
many of these cases were classified as
Stage 0 (6.9%) or Stage 3 (21.5%)
infection (i.e., cases diagnosed in early
infection or late infection, respectively).
Early and late diagnoses represent
recent failures in prevention and testing
systems, and opportunities to
E:\FR\FM\05FEN1.SGM
05FEN1
Agencies
[Federal Register Volume 89, Number 24 (Monday, February 5, 2024)]
[Notices]
[Pages 7710-7711]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02178]
[[Page 7710]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for Health Statistics, Meeting of the ICD-10
Coordination and Maintenance Committee
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), National
Center for Health Statistics (NCHS), Classifications and Public Health
Data Standards Staff, announces the following meeting of the ICD-10
Coordination and Maintenance (C&M) Committee. This meeting is open to
the public, limited only by the number of audio lines available. Online
registration is required.
DATES: The meeting will be held on March 19, 2024, from 9 a.m. to 5
p.m., EDT, and March 20, 2024, from 9 a.m. to 5 p.m., EDT.
ADDRESSES: This is a virtual meeting. Register in advance at https://cms.zoomgov.com/webinar/register/WN_zqbhSXNtSEmAVWJhs4-4kA. The Webinar
ID is 161 010 6901; the Passcode is 681647. After registering, you will
receive a confirmation email containing information about joining the
meeting. Further information will be provided on each of the respective
web pages when it becomes available. For CDC, NCHS: https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm. For the Centers for
Medicare & Medicaid Services, Department of Health and Human Services:
https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials.
FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Medical Classification
Specialist, National Center for Health Statistics, Centers for Disease
Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782-
2064. Telephone: (301) 458-4454; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is
a public forum for the presentation of proposed modifications to the
International Classification of Diseases, Tenth Revision, Clinical
Modification (CM) and ICD-10 Procedure Coding System (PCS).
Matters to be Considered: The tentative agenda will include
discussions on the ICD-10-CM and ICD-10-PCS topics listed below. Agenda
items are subject to change as priorities dictate. Please refer to the
posted agenda for updates one month prior to the meeting.
ICD-10-PCS Topics:
1. Restriction Using Thoracoabdominal Branch Endoprosthesis *
2. Tibiotalocalcaneal Fusion with Fixation Implant *
3. Fiber Optic 3D Real-time Device Guidance **
4. Visualization and Analysis of Brain Networks in Magnetic Resonance
Imaging *
5. Lymphatic Bypass
6. Performance of Circulatory Filtration
7. Quantitative Antimicrobial Susceptibility Testing of Blood Cultures
8. Transcatheter Tricuspid Valve Replacement *
9. Cellular Assessment via Microfluidic Deformability Cytometry **
10. Fixation of Lumbar Facet Joint
11. Extracorporeal Blood Pathogen Removal **
12. Application of prademagene zamikeracel **
13. Adoptive Immune Therapy
14. Administration of dasiglucagon
15. Drug-eluting Resorbable Scaffold System
16. Continuous Monitoring and Assessment of Vascular Blood Flow *
17. Paclitaxel-coated Balloon Catheter for Percutaneous Coronary
Intervention
18. Division of Bioprosthetic Aortic Valve Leaflets **
19. Computer-aided Triage and Notification for Measurement of
Intracranial Cerebrospinal Fluid Flow *
20. Implantation of Bioengineered Vessel **
21. Rapid Antimicrobial Susceptibility Testing of Blood Cultures *
22. Stereoelectroencephalographic Radiofrequency Ablation of Brain and
Nervous Tissue
23. Insertion of Antibiotic Instilling Joint Spacer **
24. Posterior Fixation of the Thoracolumbar Spine *
25. Section X Updates
26. Addenda and Key Updates
27. Administration of bentracimab **
28. Administration of cefepime-taniborbactam *
29. Administration of ceftobiprole medocaril *
30. Administration of obecabtagene autoleucel **
31. Administration of odronextamab *
32. Administration of Orca-T **
33. Administration of RP-L201 (marnetegragene autotemcel) *
34. Administration of zanidatamab **
35. Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension for
Hepatic Portal Vein Infusion *
* Requestor has submitted a new technology add-on payment (NTAP)
application for FY 2025 consideration.
** Request is for an October 1, 2024, implementation date, and the
requestor intends to submit an NTAP application for FY 2026
consideration.
Presentations for procedure code requests are conducted by both the
requestor and the Centers for Medicare & Medicaid Services (CMS) during
the C&M Committee meeting. Discussion from the requestor generally
focuses on the clinical issues for the procedure or technology,
followed by the proposed coding options from a CMS analyst. Topics
presented may also include requests for new procedure codes that relate
to a new technology add-on payment (NTAP) policy request.
CMS has modified the approach for presenting the new NTAP-related
ICD-10-PCS procedure code requests that involve the administration of a
therapeutic agent. For the March 19-20, 2024, ICD-10 C&M Committee
meeting, consistent with the requirements of section 1886(d)(5)(K)(iii)
of the Social Security Act, applicants submitted requests to create a
unique procedure code to describe the administration of a therapeutic
agent, such as the option to create a new code in Section X within the
ICD-10-PCS procedure code classification. CMS will initially display
only those meeting materials associated with the NTAP-related ICD-10-
PCS procedure code requests that involve the administration of a
therapeutic agent on the CMS website in early March 2024 at: https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials.
The nine NTAP-related ICD-10-PCS procedure code requests that
involve the administration of a therapeutic agent are:
1. Administration of bentracimab **
2. Administration of cefepime-taniborbactam *
3. Administration of ceftobiprole medocaril *
4. Administration of obecabtagene autoleucel **
5. Administration of odronextamab *
6. Administration of Orca-T **
7. Administration of RP-L201 (marnetegragene autotemcel) *
8. Administration of zanidatamab **
9. Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension for
Hepatic Portal Vein Infusion *
* Requestor has submitted an NTAP application for FY 2025
consideration.
[[Page 7711]]
** Request is for an October 1, 2024, implementation date, and the
requestor intends to submit an NTAP application for FY 2026
consideration.
These topics will not be presented during the March 19-20, 2024,
meeting. CMS will solicit public comments regarding any clinical
questions or coding options included for these procedure code topics in
advance of the meeting continuing through the end of the respective
public comment periods. Members of the public should send any questions
or comments to the CMS mailbox at: [email protected].
CMS intends to post a question-and-answer document in advance of
the meeting to address any clinical or coding questions that members of
the public may have submitted. Following the conclusion of the meeting,
CMS will post an updated question-and-answer document to address any
additional clinical or coding questions that members of the public may
have submitted during the meeting that CMS was not able to address or
that were submitted after the meeting.
The NTAP-related ICD-10-PCS procedure code requests that do not
involve the administration of a therapeutic agent and all non-NTAP-
related procedure code requests will continue to be presented during
the virtual meeting on March 19, 2024, consistent with the standard
meeting process.
CMS will make all meeting materials and related documents available
at: https://www.cms.gov/medicare/coding-billing/icd-10-codes/icd-10-coordination-maintenance-committee-materials. Any inquiries related to
the procedure code topics scheduled for the March 19, 2024, ICD-10 C&M
Committee meeting day that are under consideration for October 1, 2024,
implementation should be sent to the CMS mailbox at:
[email protected].
ICD-10-CM Topics:
1. Abnormal Anti-cyclic Citrullinated Peptide Antibody and/or
Rheumatoid Factor Without Current or Prior Clinical Diagnosis of
Rheumatoid Arthritis
2. APOL1-mediated Kidney Disease
3. Baked Egg Tolerance
4. Baked Milk Tolerance
5. Coding of Firearms Injuries Default
6. DLG4-related Synaptopathy
7. Flank Anatomical Specificity
8. Glutamate Receptor, Ionotropic, Gene-related Neurodevelopmental
Disorders
9. Gulf War Illness
10. Hyperoxaluria
11. Post-exertional Malaise
12. SCN2A-related Disorders
13. SLC6A1-related Disorders
14. STXBP1-related Disorders
15. Usher Syndrome
16. Addenda
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-02178 Filed 2-2-24; 8:45 am]
BILLING CODE 4163-18-P